

**From:** Prof. Leslie Lai – EMD Chair  
Prof. Garry John – C-EUBD Chair

**Date** November 5<sup>th</sup>, 2015

**Ref:** New Committee  
“Education in the Use of Biomarkers in Diabetes (C-EUBD)”

**Education and Management  
Division (EMD)**

**Chair**

**Prof. Leslie LAI**  
Department of Medicine  
Gleneagles Kuala Lumpur  
282 & 286 Jalan Ampang  
50450 Kuala Lumpur – Malaysia  
Tel: +603 42510433  
Fax: +603 42520433  
e-mail: lesliecharleslai@gmail.com

**Secretary and VLP Chair**

**Dr. Elizabeth A FRANK**  
Learning 2 Lead Consultants  
101 Begonia  
Sankalap Central Park  
Yadavagiri Mysore 570020  
INDIA  
Tel: +91 821 2432321  
e-mail: anet21frank@gmail.com

**Member**

**Prof. Paolo FORTINA**  
Kimmel Cancer Center  
Dept of Cancer Biology  
Thomas Jefferson University  
1009 Bluemle Life Sciences  
Building  
233 South 10th Street  
Philadelphia, PA 19107  
USA  
Tel: +1 215 955-068  
Fax: +1 215 503-9142  
e-mail: paolo.fortina@jefferson.edu

**Member**

**Dr. Ana Leticia MASELLI**  
6a. Ave. 8-92 zona 9  
Guatemala City  
GUATEMALA  
e-mail:  
analeticiamaselli@yahoo.com

**Corporate Representative**

**Dr. Christoph EBERT**  
Roche Diagnostics GmbH  
Nonnenwald 2  
D-82377 Penzberg  
GERMANY  
Tel: +49 8856 603741  
Fax: +49 8856 603752  
e-mail: christoph.ebert@roche.com

**IFCC OFFICE**

Via Carlo Farini 81  
20159 Milano, Italy  
Tel: +39 02 66809912  
Fax: +39 02 60781846  
e-mail: [ifcc@ifcc.org](mailto:ifcc@ifcc.org)  
<http://www.ifcc.org>

**To: All National Representatives of the Full and Affiliate Member Societies  
All Corporate Members' Representatives**

Dear Colleagues

The IFCC has a highly successful history in developing all aspects of standardisation and quality related to Haemoglobin A<sub>1c</sub> measurement. The IFCC-WG on Haemoglobin A<sub>1c</sub> standardisation successfully developed a reference method and primary reference material, which has enabled manufacturers worldwide to standardise their methods to a reference measurement procedure. The working group was superseded by a Task Force on implementation of Haemoglobin A<sub>1c</sub> standardisation; this Task Force successfully developed and published quality standards for Haemoglobin A<sub>1c</sub> measurement.

As global standardisation has now been established, the IFCC Executive Board decided to re-focus and explore educational aspects relating to diabetic monitoring and diagnosis including assessing the value of new diabetes markers. A new Committee reporting to the Education and Management Committee will be formed; members will have a proven interest in scientific and/or educational aspects of diabetes.

The specific terms of reference for this Committee are:

1. To maintain and further develop the network of reference laboratories for the measurement of HbA<sub>1c</sub> (through collaboration with C-TLM)
2. To work in partnership with WHO and IDF to continue to promote the reporting of HbA<sub>1c</sub> in line with the consensus statement
3. To work in partnership with WHO and IDF to facilitate the development and implementation of international guidelines for the use of HbA<sub>1c</sub> in the diagnosis of diabetes
4. To work with IFCC Corporate Members to develop a consensus position on the information to be included in the Instructions for Use (IFU) as it relates to the clinical use of HbA<sub>1c</sub> methods
5. Develop quality targets for the measurement of HbA<sub>1c</sub> and other biomarkers, and on the basis of these targets, and in conjunction with professional bodies, advise on the use of biomarkers for monitoring, diagnosis and screening of diabetes and glucose intolerance.
6. To work with WHO and TF-POCT to recommend best practice in the use of POCT methods for the measurement of HbA<sub>1c</sub>
7. To evaluate the clinical value of emerging biomarkers (e.g. glycated albumin) for the management of patients with diabetes and to establish whether there is a case for method harmonisation of effective new biomarkers
8. To evaluate the emerging importance of post translational modification derived products (PTMDPs), and especially Advanced Glycation End-Products (AGEs), and work with Professional bodies on the best way of developing these for use in diabetes.
9. To monitor the literature and advise on best practice in relation to laboratory aspects of diabetes.

The Committee will consist of 5 full members, including the Chair (Professor Garry John), nominated by the IFCC Member Societies and/or Corporate Members. This letter invites you to nominate one candidate for the four vacancies.

We would particularly welcome applications from candidates with experience in delivering a comprehensive diabetes laboratory service, standardisation activities or in diabetes education, although all applications will be given careful consideration.

Nominations should be directly sent to the IFCC Office ([ifcc@ifcc.org](mailto:ifcc@ifcc.org)) using the attached Application Form by November 30<sup>th</sup>, 2015.

Following approval, the candidates will be appointed for a three-year term on the Committee. A second three-year term is allowed following satisfactory review at the end of the first term by the Education and Management Division Executive Committee following consultation with the Committee Chairman.

Looking forward to receiving your nomination.

Yours sincerely

Prof. Leslie Lai

Prof. Garry John

EMD Chair

C-EUBD